RxDoctor Payments Data

Anna Fakadej, MD

Ophthalmology · Southern Pines, NCNPI 1932190261

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,395 of the $17,909 with a category attached, or 69.2%. Alcon accounts for 91.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $10,927 and has fallen 62.2% since, to $4,135 in 2025. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,909in general payments, 2019–2025

Across 77 payments — averaging $232.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$16K
  • Alcon Research LLC$980
  • Rxsight Inc$174
  • Biotissue Holdings Inc.$162
  • Glaukos Corporation$108
  • Johnson & Johnson Surgical Vision, Inc.$101
  • plus $88 from 4 others
$284,919in research payments, 2019–2025

Across 521 payments — averaging $546.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$202K
  • Kala Pharmaceuticals, Inc.$69K
  • Bausch Health US, LLC$14K

What the payments were for

  • Consulting fees$2,94016%
  • Speaking & faculty fees$12,39569%
  • Travel & lodging$1751%
  • Food & beverage$2,39913%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,909 in reported general payments places this provider in the 90th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$391,160
Medicare patients
507
Services billed
2,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate828$29,655
Difluprednate255$26,627
Ofloxacin1,133$13,252
Brimonidine Tartrate20$431
Timolol Maleate55$423
Gentamicin Sulfate54$401
Latanoprost38$304
Ketorolac Tromethamine13$245

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →